NEW YORK — PlaqueTec, a UK-based developer of biomarkers for the precision treatment of coronary artery disease (CAD), said on Tuesday that it has raised $8 million in private equity financing.

纽约-PlaqueTec是一家总部位于英国的用于精确治疗冠状动脉疾病（CAD）的生物标志物开发商，周二表示，它已通过私募股权融资筹集了800万美元。

The funding was provided by individual investor and British politician Jonathan Moynihan, the Future Fund, and undisclosed existing investors.

这笔资金由个人投资者、英国政治家乔纳森·莫伊尼汉（JonathanMoynihan）、未来基金（Future Fund）以及未透露姓名的现有投资者提供。

PlaqueTec said it will use the money to fund an ongoing trial, called BioPattern, in which the company's Liquid Biopsy System is used to collect blood samples from CAD patients for analysis using a multiomic approach and plaque imaging.

PlaqueTec表示，它将用这笔钱资助一项名为BioPattern的正在进行的试验，该试验使用该公司的液体活检系统从CAD患者身上采集血液样本，使用多组学方法和斑块成像进行分析。

PlaqueTec, which received approval from the UK Medicines and Healthcare products Regulatory Agency for the study last year, hopes the trial will help validate the biopsy system and further build out Biocarta, a bioinformatics platform designed to identify in vivo biomarkers that can group CAD patients into endotypes with defined signatures of the disease to enable personalized treatment.

PlaqueTec去年获得了英国药品和保健品管理局（UK Medicines and Healthcare products Regulatory Agency）的批准，希望该试验将有助于验证活检系统，并进一步构建Biocarta，这是一个生物信息学平台，旨在识别体内生物标志物，可以将CAD患者分为具有明确疾病特征的内型，以实现个性化治疗。

.

.